NDAORALTABLET
Approved
Jan 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 34m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIIBRYD (vilazodone HCl) is an oral small-molecule antidepressant approved in 2011 for major depressive disorder. It functions as a selective serotonin reuptake inhibitor (SSRI) with 5-HT1A receptor partial agonist activity, offering a dual mechanism to treat depression. This combination approach distinguishes it from traditional SSRIs in the antidepressant market.
$0.017BPart D
LOE ApproachingAs LOE approaches, the brand team is likely consolidating around defending market share and managing transition planning; expect leaner commercial operations focused on differentiation and patient retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VIIBRYD offers limited career growth opportunities given its LOE-approaching status and minimal linked job postings. Roles available are typically defensive, focused on competitive positioning and managed care negotiations rather than launch or expansion activities.
Brand ManagerField Sales Representative
Worked on VIIBRYD at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.